We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 26

German Federal Cartel Office encourages German drug makers to challenge purchasing cooperation of health insurance companies before courts

  • Bird & Bird
  • -
  • Germany
  • -
  • March 26 2007

On 22 November 2006, the German Federal Cartel Office (FCO) wrote a letter to all German associations of pharmaceutical companies informing them that the FCO will not commence proceedings against the cooperation regarding procurement planned by 16 health insurance companies (Allgemeine Ortskrankenkassen, “AOK”), however, the FCO encouraged the associations to challenge the procurement cooperation before the courts

Summary of the European Commission's Pharmaceutical Sector Inquiry Preliminary Report

  • Bird & Bird
  • -
  • European Union
  • -
  • December 31 2008

This article summarises the key findings laid out in the European Commission's Pharmaceutical Sector Inquiry Preliminary Report, which was published on Friday 28 November 2008

Dispute between the Federal Ministry of Health and the Federal Cartel Office over privatisation of hospitals

  • Bird & Bird
  • -
  • Germany
  • -
  • October 30 2007

The Federal Cartel Office has approved the acquisition of the psychiatric clinic Wunstorf from the federal state of Lower Saxony by the Klinikum Region Hannover GmbH only after imposing conditions

Judgment of the European Court of Justice in the GSK dual pricing case

  • Bird & Bird
  • -
  • European Union
  • -
  • October 13 2009

The European Court of Justice ("ECJ") has given judgment on the appeals of the European Commission, GSK and two trade associations against the judgment of the European Court of First Instance ("ECFI") in the GSK dual pricing parallel exports case, Joined Cases C-50106P, C-51506P and C-51906P, GlaxoSmithKline Services Unlimited, formerly Glaxo Wellcome plc v Commission and Commission, EAEPC and Aseprofar v GlaxoSmithKline Services Unlimited, formerly Glaxo Wellcome plc

The Competition Council accepts commitments in relation to distribution of pharmaceuticals

  • Bird & Bird
  • -
  • France
  • -
  • October 30 2007

The Competition Council has accepted commitments from four pharmaceutical groups following its investigation into the distribution of medicines

Pfizer’s arrangements with Unichem

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • October 30 2007

The High Court dismissed an application for an interim injunction by AAH Pharmaceuticals Limited and seven other pharmaceutical wholesalers to restrain the implementation of Pfizer Limited’s new single “direct to pharmacy” distribution arrangements for its prescription drugs in the UK

Safe for now

  • Bird & Bird
  • -
  • United Kingdom, USA
  • -
  • March 12 2008

In this article, Jeremy Robinson, Senior Associate in Bird & Bird’s International Competition Group, considers how the fight against cartels will be affected by today’s rulings in the House of Lords

German Federal Cartel Office imposes fine against Rossmann for below-cost selling

  • Bird & Bird
  • -
  • Germany
  • -
  • March 26 2007

The German Federal Cartel Office (FCO) has imposed a fine of 300,000 against Rossmann

Common exclusive purchase obligations null and void?

  • Bird & Bird
  • -
  • European Union
  • -
  • October 30 2008

The pharmaceutical market is currently undergoing severe changes due to the imminent or past expiration of patent protection for many blockbuster pharmaceuticals and political pressure for cheaper pharmaceuticals as considered by the European Commission’s sector inquiry into competition in the pharmaceutical sector which started in January 2008

Monitor to gain competition law powers from 1 April

  • Bird & Bird
  • -
  • United Kingdom
  • -
  • February 11 2013

Monitor, the NHS regulator, is to have powers to apply competition law to healthcare service providers from 1 April 2013. The competition law